Pharmacokinetic considerations in abuse liability evaluation

Br J Addict. 1991 Dec;86(12):1601-6. doi: 10.1111/j.1360-0443.1991.tb01754.x.

Abstract

The behavioral effects of a drug are related to three factors: its intrinsic pharmacological activity, its physicochemical properties, and its pharmacokinetic parameters. In many cases differences in absorption, distribution, metabolism, and elimination may explain the different abuse liability profiles of drugs from within the same pharmacological class. Rapid absorption rate and high lipid solubility are the most important factors contributing to early drug concentrations in the brain. Differences in drug metabolism may be related to dose-dependent kinetics, first-pass metabolism, and variations in genetic traits (e.g. poor or extensive metabolizers). Metabolic pathways may produce active metabolites with similar or greater pharmacological activity than the parent substance. Drugs with a rapid elimination rate have been associated with greater self-administration and with early emergence of withdrawal symptoms. More pharmacokinetic studies are needed in human drug abuse liability evaluations. Knowledge of the plasma concentrations of drugs and their pharmacokinetic parameters can be essential to interpret differences among similar drugs in human abuse liability assessments.

Publication types

  • Review

MeSH terms

  • Drug Evaluation / methods
  • Humans
  • Psychotropic Drugs / pharmacokinetics*
  • Risk Factors
  • Substance-Related Disorders / blood*
  • Substance-Related Disorders / prevention & control*

Substances

  • Psychotropic Drugs